Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume 2021 eBook
Issue 3
Pages: 23–33
Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
ipopba - Stock.adobe.com
In pharma applications, consistent sampling and testing nomenclature is critical for data integrity and compliance with specifications and regulatory standards. Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
Guidance documents within the pharma industry and other regulated sectors, however, offer conflicting information. This review of regulatory and compendial standards reveals the scope of the problem.
This article provides a review of available analytical nomenclature, recommended naming for individual steps, and terms used in the process flows. Part two of this paper proposes a simplified approach for sampling and testing nomenclature.
Read this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.
About the author
Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 23–33
Citation
When referring to this article, please cite it as C. Burgess, “Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).
Articles in this issue
Understanding Combination Product Regulations
Considering Titanium Dioxide Regulatory Changes
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Changing the Course of Drug Shortages
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
Industry Organizations Assist Pharma During the Pandemic and Beyond
Mapping Out Pharma’s Regulatory Future in Europe
Recent Videos
Related Content
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025Article
The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
